INTRODUCTION
CD40 is a M r 50,000 transmembrane protein in the tumor necrosis factor (TNF) receptor superfamily, which includes CD30 and CD95 (Fas/Apo-1). CD40-CD40 ligand (CD40L) interactions play a critical role in the regulation of humoral and cellular immune responses. Activation of CD40, using CD40L transfectants, soluble CD40L (sCD40L), or anti-CD40 monoclonal antibodies (mAbs), is critical for normal B-cell growth, differentiation, and isotype switching. We and others have demonstrated that CD40 is expressed on the majority of primary multiple myeloma (MM) cells (1) (2) (3) . Specifically, triggering human MM cells via CD40 induces increased homotypic and heterotypic cell adhesion, up-regulation of various cell surface markers (4), translocation of Ku86/Ku70 to the cell surface (5, 6) , and increased interleukin 6 (IL-6) secretion (4, 7) . Ligation of CD40 with sCD40L or an anti-CD40 mAb also induces vascular endothelial growth factor (3) and urokinase-type plasminogen activator (8) , suggesting its role in MM homing and migration. Several studies show that CD40 stimulation also suppresses human MM cell growth (9 -12) . Although the mechanism by which CD40 triggers growth arrest and apoptosis in MM cells is not delineated, wild-type p53 function is involved in these processes (9) .
Because human MM remains incurable, novel biologically based therapies urgently are needed. In other cancers, mAbs and mAb-based reagents have shown clinical efficacy (13) . For example, immunotherapy using antibody-targeting CD20 (rituximab), alone and in combination with chemotherapy, has been effective for management of B-cell lymphoproliferative diseases (14, 15) . However, few MM patients express CD20 (16) . The mAbs targeting CD40 on patient tumor cells represent an attractive therapeutic strategy for MM, and a variety of carcinomas also highly express CD40, broadening its potential therapeutic application. Many investigators have reported that anti-CD40 mAb can enhance antitumor activity and immunity. For example, murine anti-CD40 mAb blocked IL-6 secretion induced by MM cell adhesion to bone marrow stromal cells; because IL-6 is a key growth and survival factor for human MM cells, blockade of IL-6 secretion abrogates MM cell growth in the bone marrow milieu (4) . In addition, anti-CD40 immunotoxin can effectively kill B-lineage acute lymphoblastic leukemia and non-Hodgkin's lymphoma (17) . In vivo treatment of severe combined immunodeficiency mice bearing human B lymphomas with anti-CD40 antibodies inhibited tumor progression and enhanced survival (18, 19) . Funakoshi et al. (20) demonstrated that murine anti-CD40 mAb was more effective at killing tumors in human B-cell lymphoma-xenografted severe combined immunodeficiency mice, in the absence of Fc receptor-bearing effector cells, than was anti-CD20 mAb to kill tumors. Subsequently, van Mierlo et al. (21) reported that systemic in vivo administration of agonistic anti-CD40 antibodies resulted in tumor eradication mediated via dendritic cell-induced CD8 ϩ T-cell responses. Honeychurch et al. (22) most recently showed that anti-CD40 mAb in combination with irradiation results in CD8 T-cell-dependent immunity against B-cell lymphoma in mice, suggesting that combining irradiation with anti-CD40 mAb may provide a more potent therapeutic approach.
In the present study, we evaluated the direct impact of SGN-40 humanized anti-CD40 mAb on MM cell lines and patient cells (CD40 ϩ CD138 ϩϩ ). SGN-40 was engineered from SGN-14 mouse mAb, which showed significant antitumor activity against human HS-Sultan and IM-9 cell line-xenografted severe combined immunodeficiency mice, without adverse effects on human normal B cells (23) . We recently showed that SGN-40 triggered antibody-dependent cell-mediated cytotoxicity against CD40-expressing MM cell lines and patient cells, supporting its potential therapeutic use in human MM (24) . Moreover, the tumoricidal effects of SGN-40 could not be solely attributed to enhancing effector functions of antibody-dependent cell-mediated cytotoxicity. To examine for direct induction of apoptosis, as is induced in malignant B lymphocytes by rituximab, we specifically examined the effects of SGN-40 on CD40 ϩ and CD138 ϩ MM.1S and MM.1R cell lines and on patient MM cells (25) . SGN-40-induced cytotoxicity against MM cells is associated with upregulation of cytotoxic ligands of the TNF family FasL, TNF-related apoptosis-inducing ligand (TRAIL), and TNF-␣. Moreover, SGN-40 suppressed IL-6 receptor (IL-6R) expression at mRNA and protein levels, associated with inhibition of IL-6-mediated, but not insulinlike growth factor I (IGF-I)-mediated, MM cell growth and survival. These data provide the preclinical framework for the evaluation of SGN-40 as a novel therapy to improve patient outcome in MM.
MATERIALS AND METHODS
Cell Culture and Treatments. The CD40 ϩ and CD138 ϩϩ human MMderived cell lines MM.1S and MM.1R were maintained as described previously (8) . Freshly isolated tumor cells (CD40 ϩ , CD138 ϩϩ ) from MM patients were obtained after informed consent and purified as described previously (8) To determine whether down-regulation of CD40 by SGN-40 occurs by the proteasome pathway, cells were pretreated with proteasome inhibitor PS341 at a nontoxic dose (2 nM) for 2 h before treatment with sCD40L or SGN-40. To define the effect of a lysomotropic agent on SGN-40-mediated down-regulation of CD40, cells were pretreated with 10 mM ammonium chloride (Sigma, St. Louis, MO) for 2 h beforeagacctgcgtgctgatcgt-3Ј and 5Ј-gaccagttcaccattcctc-3Ј; for TNF-␣, 5Ј-cttctgcctgctgcactttgga-3Ј and 5Ј-tcccaaagtagacctgcccaga-3Ј; and for CD40L, 5Ј-caccttctctgccagaagataccatttcaa-3Ј and 5Ј-ttatgaagactcccagcgtcacgtccacca-3Ј. IL-6R cDNA was amplified by reverse transcription-PCR using a primer pair (5Ј-cagctgagaacgaggtgtcc-3Ј and 5Ј-gcagcttccacgtcttcttga-3Ј) flanking the transmembrane coding region of IL-6R. The primer pair for gp130 is 5Ј-atactggagtgactggagtg-3Ј and 5Ј-catcttgtgagagtcacttc-3Ј. Templates initially were denatured at 95°C for 5 min, and then a cycle at 95°C for 45 s, 56°C for 45 s, and 72°C for 1 min was repeated 25 times, followed by a final extension at 72°C for 5 min. The number of amplification cycles chosen for each reaction was determined to be within the linear range of the assay. PCR amplification of glyceraldehyde-3-phosphate dehydrogenase (GADPH) from the same reverse-transcribed cDNA template under the same conditions served as an internal control, with the primer pair of 5Ј-ccatggagaaggctgggg-3Ј and 5Ј-caaagttgtcatggatgacc-3Ј. Real-time reverse transcription-PCR was performed on a TaqMan ABI 7700 Sequence Detection System (Applied Biosystems, Foster City, CA) using heat-activated TaqDNA polymerase (Amplitaq Gold, Applied Biosystems). Primers for ␤-actin are 5Ј-acgtggacatccgcaaag-3Ј and 5Ј-tgcatcctggtcggcaatg-3Ј. treated for 6 h with SGN-40 (10 g/ml) and then cocultured with the de novo protein synthesis inhibitor CHX (0.2 g/ml) for an additional 48 h. Cell viability was assayed by 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide. SGN-40 and CHX triggered 50 -60% cell killing in both cell lines (Fig. 1B, left) . Treatment with isotype control immunoglobulin alone or with CHX also did not induce cytotoxicity (Fig. 1B, right) . SGN-40 triggered 20 -30% cell cytotoxicity in two patient MM cells. In the presence of CHX at a nontoxic dose (0.2 g/ml), SGN-40-induced cell cytotoxicity was enhanced significantly (Fig. 1C ). These results suggested that endogenous production of cytotoxic cytokines might mediate SGN-40-induced cell death in CD40-expressing MM cells; therefore, we investigated whether SGN-40 treatment modulated expression of FasL and other cytotoxic members of the TNF superfamily, i.e., TNF-␣ and TRAIL (Apo-2L). Expression of FasL, TNF-␣, and TRAIL increased after SGN-40 treatment, although the kinetics of induction of each gene varied (Fig. 1D) .
RESULTS

Cytotoxic
SGN-40 Does Not Alter sCD40L-Induced Phosphorylation of AKT, IB␣, and ERK in MM.1S Cells. We next examined the signaling pathways induced by SGN-40 in MM.1S cells. Serumstarved MM.1S cells were treated with either SGN-40 or sCD40L (5 g/ml for 0 -40 min). Cell lysates were subjected to immunoblot analysis to detect activation of AKT, inhibitor of nuclear factor-B␣ (IB␣), and extracellular signal regulated kinase (ERK)-1/2 using phospho-specific antibodies. CD40 activation by sCD40L induces phosphorylation of AKT, IB␣, and ERK ( Fig. 2A, right) as shown previously (8) . In contrast, SGN-40 did not activate either AKT or IB␣ phosphorylation. Phosphorylation of ERK was observed following SGN-40 stimulation, less potent than triggered by sCD40L. Little, if any, phosphorylation of AKT and IB␣ was observed, even at increasing concentrations of SGN-40 (up to 1000 g/ml; Fig. 2B ).
We next studied whether combination treatments with these agents altered downstream signaling. MM.1S cells were treated with SGN-40 or sCD40L, alone or together, for 7 min. SGN-40 (5 g/ml) did not induce phosphorylation of AKT and IB␣, whereas sCD40L either alone or together with SGN-40 (5 and 10 g/ml) induced activation of these signaling proteins (Fig. 3) . Phosphorylation of ERK-1/2 was similarly induced by SGN-40, either alone or with sCD40L. MM.1S cells then were pretreated with increasing concentrations (5-1000 g/ml) of SGN-40 for 30 min before stimulation with sCD40L (5 g/ml). As shown in Fig. 3B, SGN-40 at either 50 or 1000 g/ml did not significantly inhibit sCD40L-induced phosphorylation of AKT.
Pretreatment of MM Cells with SGN-40 Inhibits sCD40L-Mediated Phosphorylation of AKT/IB␣ and ERK Pathways.
We next measured the levels of CD40 following treatment of MM.1S cells with SGN-40 versus sCD40L. Cells were treated with sCD40L (5 g/ml), SGN-40 (20 g/ml), or both for the indicated time intervals. CD40 levels were measured by immunoblot analysis using anti-CD40 antibody. No changes in CD40 levels were noted at 20 min to 24 h in untreated cells (labeled Lane 1 for each time point; Fig. 4A ). sCD40L treatment for 20 min to 24 h also did not alter levels of CD40 (Fig. 4A , Lane 2 compared with Lane 1). In contrast, SGN-40 triggered down-regulation of CD40 after 4 h (Fig. 4A, Lane 3 ) and significant inhibition of CD40 expression by 24 h. A, serum-starved MM.1S cells were incubated with SGN-40 (5-10 g/ml) for 7 min in the presence or absence of sCD40L (5-10 g/ml). Isotype control immunoglobulin (5 g/ml) was used as a control. Cell lysates were subjected to immunoblot analysis using anti-pAKT, pIB␣, and pERK1/2 antibodies, and with anti-AKT antibody as a loading control. B, serum-starved MM.1S cells were pretreated with various concentrations (5-1000 g/ml) of SGN-40 for 30 min before stimulation with 5 g/ml sCD40L (ϩ) for 7 min. Cellular proteins then underwent immunoblot analysis with anti-pAKT and with anti-〈⌲⌻ as a loading control. Because many signaling molecules are regulated by ubiquitination followed by degradation by the proteasome, we next investigated whether the mechanism by which SGN-40 down-regulates CD40 is via the proteasome pathway. Cells were pretreated for 2 h with a nontoxic dose (2 nM) of proteasome inhibitor PS341, followed by sCD40L or SGN-40 for 22 h. As shown in Fig. 4B , PS341 did not block down-regulation of CD40 by SGN-40 compared with cells treated with only SGN-40 or DMSO vehicle control. This suggests that down-regulation of CD40 induced by SGN-40 does not occur via proteasomal degradation. To determine whether down-regulation of CD40 was mediated by an endocytic pathway, cells then were preincubated with ammonium chloride (10 mM for 2 h) and then treated with sCD40L or SGN-40 (26) . Ammonium chloride increases pH of endosomes, thereby inhibiting the endocytic pathway. Pretreatment of cells with ammonium chloride blocked SGN-40-induced down-regulation of CD40 (Fig. 4C) . This result suggests that down-regulation of CD40 triggered by SGN-40 occurs via a lysosomal and endocytic pathway.
We next examined whether MM.1S cells respond to sCD40L stimulation after antibody-induced down-regulation of CD40. Cells were pretreated with either sCD40L or SGN-40 for 24 h and then either untreated or treated with additional sCD40L (5 g/ml). Phosphorylation of AKT, IB␣, and ERK was induced by sCD40L (Fig. 5, Lanes  1-3) as shown previously. In cells pretreated with sCD40L for 24 h and then treated with additional sCD40L for 7 min, AKT, IB␣, and ERK were phosphorylated (Fig. 5, Lanes 4 and 5) . In contrast, in cells pretreated with SGN-40 followed by treatment with sCD40L for 7 min, phosphorylation of AKT, IB␣, and ERK was undetected (Fig.  5, Lanes 6 and 7) . Cells pretreated with SGN-40 and re-treated with additional SGN-40 did not show enhanced AKT, IB␣, and ERK phosphorylation (data not shown). Thus, 24-h pretreatment of MM.1S cells with SGN-40 blocks sCD40L-induced phosphorylation of AKT and IB␣ and activation of ERK. In contrast, cells treated with sCD40L for 24 h were stimulated by subsequent treatment with additional sCD40L. These data suggest that down-regulation of CD40 by SGN-40 blocked the ability of sCD40L to trigger phosphatidylinositol 3Ј-kinase/AKT, nuclear factor B, and ERK signaling.
Pretreatment of MM Cells with SGN-40 Renders Them Refractory to IL-6-, but not IGF-I-, Mediated Proliferation and Antiapoptosis.
Because IL-6 and IGF-I are key MM growth and survival factors, we next asked whether SGN-40-treated MM cells respond to these cytokines in a fashion similar to control immunoglobulin-treated cells. Dex-sensitive MM.1S and Dex-resistant MM.1R cells were pretreated with SGN-40 (20 g/ml) or control immunoglobulin for 24 h. Cells were washed, and DNA synthesis was measured after 36-h culture with IL-6 or IGF-I (0 -200 ng/ml). As shown in Fig. 6A (left) , IL-6-induced cell proliferation is significantly blocked in MM.1S and MM.1R cells pretreated with SGN-40 (P Ͻ 0.01) compared with the 2.5-3-fold increase in cell proliferation induced by IL-6 in control immunoglobulin-treated cells (Fig. 6A, left) . In contrast, IGF-I induces cell proliferation to a similar extent in SGN-40-and control immunoglobulin-treated MM.1S and MM.1R cells. We next tested whether pretreatment with SGN-40 alters IL-6-induced protection against Dex-induced apoptosis in MM.1S cells. Cells were pretreated with SGN-40 or control immunoglobulin for 24 h, washed, and then incubated with Dex (0 -10 M) for 36 h before assay for [ 3 H]thymidine incorporation. IL-6 (50 ng/ml) completely rescues Dex-induced cell death in control immunoglobulin-treated cells, whereas IL-6-induced protection against Dex was blocked significantly in SGN-40-pretreated cells (P Ͻ 0.023; Fig. 6B, left) . In contrast and as shown in Fig. 6B (right) , IGF-I-induced MM cell antiapoptosis was observed in SGN40-treated and control immunoglobulin-treated cells. These results indicate that SGN-40 pretreatment inhibits IL-6-, but not IGF-I-, mediated MM cell growth and survival.
We for 3 h and 9 h, and IL-6R levels then were measured using immunoprecipitation, followed by immunoblot analysis with anti-IL-6R antibody. As shown in Fig. 8A , a 2-4-fold suppression of IL-6R was observed in MM.1S and a patient's MM cells following 9 h of treatment with SGN-40. To confirm specific down-regulation of IL-6R expression, MM.1S and patient MM cells (MM#1) were incubated with 20 g/ml of SGN-40 or control immunoglobulin overnight, followed by assessment for IL-6R by flow cytometry. Down-regulation in IL-6R expression was seen only in SGN40-treated, but not in control immunoglobulin-treated, MM.1S cells (Fig. 8B) . In addition, SGN-40-induced down-regulation of IL-6R expression was prevented by mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor U0126 and PD98059 (Fig. 8C ) but unaffected by inhibitors of either phosphatidylinositol 3Ј-kinase or p38 mitogenactivated protein kinase (Fig. 8C) . These results suggest that mitogenactivated protein kinase/ERK signaling mediates SGN-40-induced inhibition of cell surface IL-6R expression.
To explore whether transcriptional mechanisms are involved in down-regulation of IL-6R induced by SGN-40, we next analyzed IL-6R mRNA in MM.1S cells following treatment with SGN-40 (20 g/ml) or control immunoglobulin. IL-6R reverse transcription-PCR shows two specific products with a 94-bp size difference in all of the samples (Fig. 9A) . The smaller species lacks 94 bp (exon 2), including the coding region of the transmembrane domain of the IL-6R (27) . As shown in Fig. 9A , SGN-40 treatment induced time-dependent suppression of both species of IL-6R transcripts in MM.1S cells (Lanes 4 -6) and two patients' MM cells (Lanes 7-9 and Lanes 10 -12), whereas no difference in IL-6R transcripts was found in control immunoglobulin-treated MM.1S cells (Fig. 9, Lanes 1-3) . The gp130 and GADPH mRNAs were unchanged by treatment with either SGN-40 or control immunoglobulin. IL-6 mRNA suppression following SGN-40 treatment also was confirmed by real-time reverse transcription-PCR (Fig. 9B) .
DISCUSSION
We report here that humanized anti-CD40 mAb SGN-40 treatment of CD40 ϩ and CD138 ϩ MM cell lines and patient MM cells significantly induces growth arrest and apoptosis in the presence of the de novo protein synthesis inhibitor CHX. SGN-40-induced cytotoxicity is associated with up-regulation in cytotoxic TNF ligands (i.e., FasL, TRAIL, and TNF-␣). In addition, SGN-40 suppresses expression of IL-6R protein and mRNA associated with inhibition of growth and survival of MM cells induced by IL-6 but not by IGF-I. These data support a new treatment strategy using SGN-40 to improve patient outcome in human MM.
We show that SGN-40 induces apoptosis of CD40 ϩ and CD138 partially inhibited by neutralizing anti-FasL antibody NOK1 (30% Ϯ 5%; data not shown). However, the inability of neutralizing anti-FasL antibodies to abolish completely SGN-40-mediated cytotoxicity suggests additional death signals. Exposure of MM.1S cells to SGN-40 also induced transcriptional activation of other cytotoxic members of the TNF family, such as TRAIL (Apo-2L) and TNF-␣, although with different kinetics. TRAIL induces MM apoptosis through the rapid activation of caspase-8, caspase-9, and caspase-3 (31) . Moreover, an individual neutralizing reagent only partially protects against SGN-40-induced cell death, confirming that SGN-40-mediated MM cell apoptosis occurs via targeting more than one cytotoxic ligand of the TNF family. Previous studies in human monocytes and normal plasma cells demonstrate the presence of high intracellular levels of FasL or TRAIL, which rapidly translocates to the cell surface in response to various stimuli (32) (33) (34) . Whether SGN-40 treatment regulates the redistribution of intracellular cytoplasmic pools of these cytotoxic ligands, in addition to their de novo transcription and translation, remains to be elucidated.
SGN-40-induced cytotoxicity in MM cells is enhanced by inhibition of protein synthesis. In particular, CHX blocks the production of protective antiapoptotic proteins (i.e., FLIP), thereby unmasking the cytotoxic potential of SGN-40. CHX-induced reduction of the shortlived antiapoptotic FLIP protein is associated with enhanced SGN-40-induced apoptosis in MM.1S cells (data not shown). Although the molecular basis for SGN-40-dependent sensitization to apoptosis in MM cells is not understood completely, this requirement of protein synthesis inhibition for efficient killing reveals a mechanism whereby MM cells, via activation of antiapoptotic cascades including AKT, Bcl-2, and Mcl-1, may escape CD40-mediated cytotoxicity. Although the ability of these pathways to block CD40-mediated cell death remains to be verified, previous studies have implicated Bcl-2, BclxL, and AKT in suppression of TRAIL-and Fas-induced apoptosis in MM (35, 36) .
In vitro studies have demonstrated internalization of CD40 after ligation by mAb (37, 38) . Our data indicate that SGN-40 caused down-regulation of CD40 via the endosomal endocytic, but not the proteasome-ubiquitin, pathway. It is possible that SGN-40 causes increased endocytosis without allowing for receptor recycling to the membrane, resulting in a net decrease in cell surface levels over time. An increase in receptor turnover leading to down-modulation of HER-2/c-erbB-2 or IGF-I receptor has been reported with specific mAbs against these receptors (39, 40) . In addition, rituximab therapy leads to down-regulation of CD20 expression at protein and mRNA in cells from treated patients (41) . This down-modulation of targeted receptors may have important implications for scheduling and dosing, not only of anti-CD20 but also of potential novel anti-CD40 therapies.
We found down-regulation of IL-6R by SGN-40, correlating with decreased IL-6 downstream signaling and function. Because IL-6 is the major growth and survival factor for human MM, decreased IL-6R induced by SGN-40 treatment would inhibit MM cell growth and survival in the bone marrow milieu. These results are consistent with recent studies demonstrating that IFN-␣ (42) or IFN-␥ (43, 44) significantly inhibits membrane IL-6 binding IL-6R (gp80) protein and mRNA in human plasma cell lines. Since IFN-␥ up-regulates CD40 expression, it may also result in additional inhibition of IL-6R expression induced by SGN-40. In contrast to its effects on IL-6 signaling, SGN-40 did not alter the proliferative and antiapoptotic effects induced by IGF-I. The mechanism by which SGN-40 treatment induces differential responses of MM cells to IL-6 and IGF-I may, at least in part, be explained by differential changes of their cognate receptors because we could not detect any changes of IGF-I receptor at either protein and mRNA levels induced by SGN-40 treatment (data not shown).
In summary, the humanized anti-CD40 mAb SGN-40 has direct anti-MM effects that are independent of antibody-dependent cellmediated cytotoxicity as we reported previously (24) . SGN-40 mediates apoptosis in human MM cells in the presence of CHX, and SGN-40 up-regulates cytotoxic ligands belonging to the TNF family. In addition to regulating CD40-mediated cytotoxicity, these ligands and/or their receptors also are important in apoptosis induced by a broad spectrum of stimuli, including chemotherapy and radiation. Importantly, inhibition of IL-6R expression by SGN-40 renders MM cells refractory to IL-6-induced proliferative and protective effects, thereby inhibiting MM cell growth and survival in the bone marrow microenvironment. These results provide the framework for the clinical evaluation of SGN-40 to improve patient outcome in MM.
